Vesalio Introduces New Neurovascular Devices: NeVa™ VS and NeVa™ 3.0 mm Thrombectomy System

Vesalio, a global innovator in vascular interventions, has launched two new neurovascular devices in Europe following CE Mark certification: the NeVa™ VS for treating cerebral vasospasm after aneurysmal subarachnoid hemorrhage (aSAH), and the NeVa™ 3.0 mm Thrombectomy System for stroke management.

The NeVa™ VS device targets cerebral vasospasm, a serious condition that can lead to delayed cerebral ischemia. 

Already approved in the U.S. under a Humanitarian Device Exemption, NeVa™ VS provides a safer alternative to balloon angioplasty by maintaining blood flow to critically narrowed vessels. 

Clinical studies indicate that more than 93% of treated vessels did not require additional intervention, highlighting its potential as a definitive therapy for cerebral vasospasm.

The NeVa™ 3.0 mm Thrombectomy System brings Vesalio’s proprietary Drop Zone™ technology to smaller, more complex arteries, expanding the number of patients eligible for mechanical thrombectomy and achieving high first-pass success in stroke treatment.

Additionally, Vesalio received FDA 510(k) clearance to extend the use of its neurovascular and peripheral aspiration catheters for distal access through microcatheter delivery, enhancing the flexibility of its catheter lineup.

These regulatory approvals strengthen Vesalio’s neurovascular offerings and reinforce the company’s commitment to delivering innovative solutions for complex vascular conditions.